gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Article

Send article

Suppression of pancreatic tumor growth in liver by systemic administration of the TRAIL Gene driven by the hTERT Promoter

Meeting Abstract

Search Medline for

  • corresponding author presenting/speaker Dietmar Jacob - Charité Campus Virchow, Klinik für Allgemeinchirurgie-, Viszeral- und Transplantationschirurgie, Berlin, Deutschland
  • Marcus Bahra - Charité Campus Virchow, Klinik für Allgemeinchirurgie-, Viszeral- und Transplantationschirurgie, Berlin
  • Guido Schumacher - Charité Campus Virchow, Klinik für Allgemeinchirurgie-, Viszeral- und Transplantationschirurgie, Berlin
  • Bingliang Fang - MD Anderson Cancer Center, Dept. of Thoracic and Cardiovascular Surgery, Houston, TX, USA
  • Jan Langrehr - Charité Campus Virchow, Klinik für Allgemeinchirurgie-, Viszeral- und Transplantationschirurgie, Berlin
  • Peter Neuhaus - Charité Campus Virchow, Klinik für Allgemeinchirurgie-, Viszeral- und Transplantationschirurgie, Berlin

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocOP469

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk579.shtml

Published: March 20, 2006

© 2006 Jacob et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Backround: Despite the availability of many therapeutic strategies and the advent of new therapeutic agents, the 5 year-survival of pancreatic cancer after diagnosis is below 5 %. Therefore, new therapeutic approaches for pancreatic cancer, especially for liver metastasis are required. In the current study we determined the combination effect of the TRAIL gene and gemcitabine in treatment of a pancreatic tumor model in the liver.

Methods: An adenoviral vector with RGD-modified fibers, expressing from the human telomerase reverse transcriptase (hTERT) promoter (designated Ad/TRAIL-F/RGD) was constructed and its antitumor activity in combination with gemcitabine was evaluated in two pancreatic cancer in vitro and in a pancreatic tumor model in nu/nu nude mice in the liver in vivo.

Results: Treatment with Ad/TRAIL-F/RGD elicited a high rate of apoptosis in human pancreatic cancer cell lines in vitro. The combination of TRAIL gene therapy and gemcitabine revealed a synergistic effect. The systemic administration of Ad/TRAIL-F/RGD via tail vein in combination with gemcitabine significantly suppressed tumor growth of pancreatic cancer in the liver, in comparison to the control group, without obvious toxic effects.

Conclusions: Our results suggest that TRAIL gene therapy in combination with gemcitabine could be a potent therapeutic approach for the treatment of advanced pancreatic cancer.